Interleukin-6 and cyclic AMP stimulate release of cathepsin B in human osteoblasts

Immunopharmacology and Immunotoxicology

Volumn 29, Issue 2, 2007, Pages 155-172

  Chae, Han Jung ^a   Ha, Ki Chan ^a   Lee, Geun Youn ^b   Yang, Sun Kyung ^b   Yun, Ki Jung ^b   Kim, Eun Cheol ^b   Kim, Sun Hee ^a   Chae, Soo Wan ^a   Kim, Hyung Ryong ^b  

^a Chonbuk National University   (South Korea)

^b Wonkwang University   (South Korea)

Author keywords

cAMP; Cathepsin B; IL 6; MAPK; Osteoblast; uPA

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CATHEPSIN B; CYCLIC AMP; CYTOKINE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; PYRROLIDINE DITHIOCARBAMATE; SN 50; UROKINASE;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; INFLAMMATION; OSTEOBLAST; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; CATHEPSIN B; CELL LINE; CYCLIC AMP; ENZYME INHIBITORS; FLUOROMETRY; HUMANS; IMIDAZOLES; INTERLEUKIN-6; NF-KAPPA B; OSTEOBLASTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; SECOND MESSENGER SYSTEMS; STIMULATION, CHEMICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 34548590952     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923970701511579     Document Type: Article

References (35)

1. Harada, S.; Rodan, G.A. Control of osteoblast function and regulation of bone mass. Nature 2003, 423, 349-355.
2. Boyle, W.J.; Simonet, W.S.; Lacey, D.L. Osteoclast differentiation and activation. Nature. 2003, 423, 337-342.
3. Rodan, G.A.; Bilezikian, J.P. Pathophysiology of osteoporosis. 2002.
4. Lacey, D.L.; Timms, E.; Tan, H.L.; Kelley, M.J.; Dunstan, C.R.; et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93, 165-176.
5. Furuyama, N.; Fujisawa, Y. Distinct roles of cathepsin K and cathepsin L in osteoclastic bone resorption. Endocr. Res. 2000, 26, 189-204.
6. Aisa, M.C.; Beccari. T.; Costanzi, E.; Maggio, D. Cathepsin B in osteoblasts. Biochim. Biophys. Acta 2003, 1621, 149-159.
7. Murray, E.J.; Grisanti, M.S.; Bentley, G.V.; Murray, S.S. E64d, a membrane-permeable cysteine protease inhibitor, attenuates the effects of parathyroid hormone on osteoblasts in vitro. Metabolism. 1997, 46, 1090-1094.
8. Bresnihan, B. Pathogenesis of joint damage in rheumatoid arthritis. J Rheumatol. 1999, 26, 717-719.
9. Murphy, G.; Ward, R.; Gavrilovic, J.; Atkinson, S. Physiological mechanisms for metalloproteinase activation. Matrix. (suppl) 1992, 1, 224-230.
10. Buttle, D.J.; Handley, C.J.; Ilic, M.Z.; Saklatvala, J.; Murata, M.; Barrett, A.J. Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases. Evidence for two converging pathways of chondrocyte-mediated proteoglycan degradation. Arthr. Rheum. 1993, 36, 1709-1717.
11. Mort, J.S.; Magny, M.C.; Lee, E.R. Cathepsin B: an alternative protease for the generation of an aggrecan 'metalloproteinase' cleavage neoepitope. Biochem. J. 1998, 335, 491-494.
12. Codorean, E.; Gabrielescu, E. Cytochemical investigation of cathepsin B in rheumatoid synovial membrane and fluid. Morphol. Embryol. (Bucur). 1985, 31, 269-274.
13. Lemaire, R.; Huet, G.; Zerimech, F.; Grard, G.; Fontaine, C.; Duquesnoy, B.; Flipo, Selective induction of the secretion of cathepsins B and L by cytokines in synovial fibroblast-like cells. Br. J. Rheumatol. 1997, 36, 735-743.
14. Trabandt, A.; Gay, R.E.; Fassbender, H.G.; Gay, S. Cathepsin B in synovial cells at the site of joint destruction in rheumatoid arthritis. Arthr. Rheum. 1991, 34, 1444-1451.
15. Mignatti, P.; Rifkin, D.B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 1993, 73, 161-195.
16. Fukumoto, S.; Allan, E.H.; Yee, J.A.; Gelehrter, T.D.; Martin. T.J.; Plasminogen activator regulation in osteoblasts: parathyroid hormone inhibition of type-1 plasminogen activator inhibitor and its mRNA. J. Cell Physiol. 1992, 152, 346-355.
17. Allan, E.H.; Martin, T.J. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts. J. Cell Physiol. 1995, 165, 521-529.
18. Daci, E.; Udagawa. N.; Martin, T.J.; Bouillon, R.; Carmeliet. G.. The role of the plasminogen system in bone resorption in vitro. J. Bone Miner. Res. 1999, 14, 946-952.
19. Leloup G., Delaisse, J.M., Vaes, G. Relationship of the plasminogen activator/plasmin cascade to osteoclast invasion and mineral resorption in explanted fetal metatarsal bones. J. Bone Miner. Res. 1994, 9, 891-902.
20. Leloup, G.; Lemoine. P.; Carmeliet, P.; Vaes, G.. Bone resorption and response to calcium-regulating hormones in the absence of tissue or urokinase plasminogen activator or of their type 1 inhibitor. J. Bone Miner. Res. 1996, 11, 1146-1157.
21. Akira, S.; Hirano, T.; Taga, T.; Kishimoto, T. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J. 1990, 4, 2860-2867.
22. Sawczenko, A.; Azooz, O.; Paraszczuk, J.; Idestrom, M.; Croft, N.M.; et al. Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. Proc. Natl. Acad. Sci. U S A. 2005, 102, 13260-13265.
23. Tilg, H.; Trehu, E.; Atkins, M.B.; Dinarello, C.A.; Mier, J.W. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994, 83, 113-118.
24. Grassl, C.; Luckow, B.; Schlondorff, D.; Dendorfer, U. Transcriptional regulation of the interleukin-6 gene in mesangial cells. J. Am. Soc. Nephrol. 1999, 10, 1466-1477.
25. Yin, F.; Wang, Y.Y.; Du, J.H.; Li, C.; Lu, Z.Z.; et al. Noncanonical cAMP pathway and p38 MAPK mediate beta2-adrenergic receptor-induced IL-6 production in neonatal mouse cardiac fibroblasts. J. Mol. Cell Cardiol. 2006, 40, 384-393.
26. Kanno, Y.; Ishisaki, A.; Yoshida, M.; Nakajima, K.; Tokuda, H.; et al. Adenylyl cyclase-cAMP system inhibits thyroid hormone-stimulated osteocalcin synthesis in osteoblasts. Mol. Cell Endocrinol. 2005, 229, 75-82.
27. Chae, H.J.; Chae, S.W.; Chin, H.Y.; Bang, B.G.; Cho, S.B.; et al. The p38 mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumor necrosis factor in osteoblasts. Bone. 2001, 28, 45-53.
28. Baeuerle, P.A. The inducible transcription activator NF-kappa B: regulation by distinct protein subunits. Biochim. Biophys. Acta. 1991, 1072, 63-80.
29. Yamamoto, T.; Ozono, K.; Kasayama, S.; Yoh, K.; Hiroshima, K.; et al. Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J. Clin. Invest. 1996, 98, 30-35.
30. Leloup, G.; Peeters-Joris, C.; Delaisse, J.M.; Opdenakker, G..; Vaes, G.. Tissue and urokinase plasminogen activators in bone tissue and their regulation by parathyroid hormone. J. Bone Miner. Res. 1991, 6, 1081-1090.
31. Fawthrop, F.W.; Oyajobi, B.O.; Bunning, R.A.; Russell, R.G.. The effect of transforming growth factor beta on the plasminogen activator activity of normal human osteoblast-like cells and a human osteosarcoma cell line MG-63. J. Bone Miner. Res. 1992, 7, 1363-1371.
32. de Bart, A.C.; Quax, P.H.; Lowik, C.W.; Verheijen, J.H. Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator-mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin-1 alpha. J. Bone Miner. Res. 1995, 10, 1374-1384.
33. Campbell, P.G..; Wines, K.; Yanosick, T.B.; Novak, J.F. Binding and activation of plasminogen on the surface of osteosarcoma cells. J. Cell Physiol. 1994, 159 (1), 1-10.
34. Goretzki, L.; Schmitt, M.; Mann, K.; Calvete, J.; Chucholowski, N.; et al. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. FEBS Lett. 1992, 297, 112-118.
35. Schmitt, M.; Goretzki, L.; Janicke, F.; Calvete, J.; Eulitz, M.; et al. Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer. Biomed. Biochim Acta. 1991, 50, 731-741.